CTVA 241220 60.00C (CTVA241220C60000) Stock Options, News & Quotes

US OptionsDetailed Quotes

CTVA241220C60000

Watchlist

3.00
-0.40-11.76%

15min DelayClose Nov 27 16:00 ET

3.50High3.00Low

Intraday

5D
Daily

News

Corteva Insider Sold Shares Worth $2,388,367, According to a Recent SEC Filing
MT Newswires16:20 ET
Evogene Says Corteva Terminates Licensing Agreement of Lavie Bio Subsidiary
TipRanks16:10 ET
Wednesday Ends With Index Decline | Wall Street Today
Kevin Travers16:08 ET
Express News | Evogene Ltd: Unit Receives Notice of Termination of Licensing Agreement With Corteva for Bio Fungicide Lead Candidates
Reuters16:04 ET
Dow Hits Another Record, Core PCE 2.8% as Expected | Live Stock
Kevin TraversNov 27 09:57 ET
S&P 500, Dow Hit Records, Trump Tariffs to Cost Hundreds of Billions | Wall Street Today
Kevin TraversNov 26 16:12 ET

Comments

Bull X Bear

Oct 16 09:41

Top Picks for US Stocks 🎯

Will Nvidia dethrone Apple as world's most valuable company?

Movers and Shakers

Apr 12 07:23

Columns Today's Morning Movers and Top Ratings: JPM, C, WFC, GTLB and More

Morning Movers
Gapping up
$Citigroup (C.US)$ shares increased by more than 2% after the bank reported revenue of $21.1 billion, surpassing analysts' expectations.
$Blackrock (BLK.US)$ 's stock grew by 2% following a quarterly report that exceeded expectations, with earnings per share of $9.81 on revenue of $4.73 billion.
$Globe Life (GL.US)$ shares surged approximately 9% in extended trading on Friday, recovering from a more than 50%...

Moomoo AI

Mar 22 09:32

Corteva's rising ROCE and efficient capital use are promising, but growing current liabilities may pose new risks. Despite this, the stock has given a decent 23% return over the past three years, indicating these developments are gaining deserved attention.

Returns Are Gaining Momentum At Corteva (NYSE:CTVA)

Moomoo AI

Mar 4 04:27

Corteva's high P/E ratio is sustained by its projected growth surpassing the broader market. Shareholders are at ease with the P/E, confident in the company's future earnings. The share price isn't anticipated to drop significantly soon under these conditions.

Corteva, Inc. (NYSE:CTVA) Not Lagging Market On Growth Or Pricing

Moomoo AI

Feb 28 06:06

The CEO of Lavie Bio, Amit Noam, expressed satisfaction at achieving this milestone with Corteva, stating that the agreement showcases Lavie Bio's technological capabilities and enables the swift introduction of groundbreaking ag-biological solutions.

Press Release: Lavie Bio Successfully Secures Second Half Advance Payment of $2.5M After Meeting Corteva's Licensing Agreement Requirements